Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
According to the latest filing disclosed by the U.S. Securities and Exchange Commission (SEC), Enphase Energy plans to sell its advanced manufacturing tax credits generated in 2025, with a total value of up to 235 million dollars.

According to the latest filing disclosed by the U.S. Securities and Exchange Commission (SEC), Enphase Energy plans to sell its advanced manufacturing tax credits generated in 2025, with a total value of up to 235 million dollars.

老虎证券老虎证券2026/04/06 20:14
Show original
This initiative aims to optimize the company's cash flow and fully leverage tax incentive policies to support business development. The tax credit transaction is expected to provide enterprises with additional funding flexibility, assisting Enphase Energy in its continued investment in technological innovation and capacity expansion. As a key player in the clean energy sector, the company remains committed to enhancing its market competitiveness through financial strategy optimization.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

US Stock Movement | SuperX AI Technology (SUPX.US) once fell more than 2.5%, hitting an intraday low of $6.46

SuperX AI Technology's stock price declined, falling more than 2.5% at one point.

智通财经•2026/10/08 16:11

BUZZ-Pacira BioSciences participated in a Viatris acquisition deal worth 1.65 billions dollars

Latest Update October 8 – Pacira BioSciences (PCRX.O) shares surged by 44%, hitting a more than three-year high at $36.30. If the rally holds, PCRX is poised for its largest single-day gain on record. Pharmaceutical company Viatris (VTRS.O) will acquire Pacira BioSciences in a $1.65 billion cash deal, offering $36.50 per share. The offer represents a premium of approximately 44.8% over Pacira’s recent closing price of $25.20. The transaction will add Pacira’s non-opioid pain medications Exparel and Zilretta to Viatris' product portfolio. Viatris shares fell 2.6% to $17.04. JPMorgan stated: “We believe this acquisition will not significantly alter VTRS' overall financial profile in the short or long term, and expect Exparel’s sales to gradually decline post-2030 due to generic market entry.” Both parties expect to complete the transaction by the end of 2026. Including intraday fluctuations, PCRX shares have risen 40.2% year-to-date, while VTRS has gained 36.8%. (For the convenience of non-English speakers, Reuters provides automated translations of its reports into several other languages. As automated translation may contain errors or lack the necessary context, Reuters does not guarantee the accuracy of automated translated texts and provides them for readers’ convenience only. Reuters assumes no liability for any damage or losses resulting from the use of automated translation.)

路透社•2026/10/08 16:11